Literature DB >> 8805991

The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro.

E Canalis1, M Hott, P Deloffre, Y Tsouderos, P J Marie.   

Abstract

In this study, we have determined the effect of the divalent strontium salt S12911 on bone cell replication and bone formation in two culture systems. In the first series of experiments, half-calvariae of newborn rats were cultured with S12911 from 24 to 96 h and labeled with 3H-thymidine for the last 6 h of culture or treated with S12911 for 24 h and labeled for 24 h with 3H-proline 24-48 h after the removal of the agent. Calvariae were then processed for histomorphometry. S12911 at 10(-3) M increased the replication of preosteoblastic cells by 30-50% after 24 h and by 60% after 96 h of treatment. This effect was specific, since the number of labeled osteoblasts and of periosteal cells was not changed. A transient 24 h treatment with S12911 at 10(-3) M increased bone formation 24 and 48 h after the removal of the agent. 3H-proline labeled surfaces and bone formation rates were increased by 20%-35%. In the second series of experiments, sequential collagenase digestions were used to isolate cell populations enriched in fibroblasts or osteoblasts (Ob) from 22 day fetal rat calvariae. Treatment with S12911 at 10(-3) M for 24 h enhanced DNA synthesis by three- to fourfold in cell populations enriched in fibroblasts and preosteoblastic cells. The effect was less pronounced and inconsistent in Ob cells. S12911 at 10(-3) M for 24 h also increased collagen and non-collagen protein synthesis by 35% in Ob cells. These data indicate that the divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro, an effect that may contribute to the previously reported effects of S12911 on trabecular bone mass in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805991     DOI: 10.1016/8756-3282(96)00080-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  94 in total

Review 1.  Is the calcium receptor a molecular target for the actions of strontium on bone?

Authors:  Edward M Brown
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

2.  Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: an open, prospective study.

Authors:  Melek Eda Ertorer; Okan Bakiner; Inan Anaforoglu; Nurzen Sezgin; Nilgun Guvener Demirag; Neslihan Bascil Tutuncu
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

3.  In vitro evaluation of bioactive strontium-based ceramic with rabbit adipose-derived stem cells for bone tissue regeneration.

Authors:  Beena Gopalan Mohan; Sivadasan Suresh Babu; Hari Krishna Varma; Annie John
Journal:  J Mater Sci Mater Med       Date:  2013-08-29       Impact factor: 3.896

4.  Bone tissue reactions to biomimetic ion-substituted apatite surfaces on titanium implants.

Authors:  Ahmed M Ballo; Wei Xia; Anders Palmquist; Carl Lindahl; Lena Emanuelsson; Jukka Lausmaa; Håkan Engqvist; Peter Thomsen
Journal:  J R Soc Interface       Date:  2012-01-25       Impact factor: 4.118

Review 5.  Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis.

Authors:  Juliet Compston
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

Review 6.  Strontium ranelate: a novel mode of action leading to renewed bone quality.

Authors:  Patrick Ammann
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

Review 7.  Strontium ranelate: a novel mode of action optimizing bone formation and resorption.

Authors:  P J Marie
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

8.  Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.

Authors:  J Y Reginster; P J Meunier
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

9.  Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis.

Authors:  P J Meunier; J Y Reginster
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

Review 10.  Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate.

Authors:  P J Marie
Journal:  Osteoporos Int       Date:  2003-03-18       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.